Literature DB >> 10714124

[Current concepts in diagnosing brain death in Germany].

F Thömke1, L S Weilemann.   

Abstract

Diagnosis of brain death requires definite evidence of an acute CNS catastrophe and exclusion of complicating medical conditions that may confound clinical assessment. Acute CNS catastrophe may be due to direct ("primary") brain damage (e.g., intracerebral hemorrhage, severe concussion, brain tumors), or indirect ("secondary") brain damage (e.g., cerebral hypoxia following cardio-pulmonary resuscitation). The cardinal findings in brain death are coma, absence of brainstem reflexes, and apnea. Persistence of these clinical signs determines brain death. In Germany, the intervals of a repeat clinical evaluation are at least 12 hours in patients with primary, and at least 72 hours in those with secondary brain damage. Electroencephalographically documented absence of electrical activity for at least 30 minutes or by means of transcranial Doppler ultrasonography or isotope angiography documented intracranial circulatory arrest also confirm brain death. Under such conditions, a repeat clinical evaluation is unnecessary in patients with clinical brain death signs. First of all, brain death is a clinical diagnosis. Confirmatory tests are not mandatory in most situations. In Germany, confirmatory tests are required in newborns, infants below the age of 2 years, and patients with infratentorial brain damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714124     DOI: 10.1007/bf03044989

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  23 in total

1.  [The depassed coma (preliminary memoir)].

Authors:  P MOLLARET; M GOULON
Journal:  Rev Neurol (Paris)       Date:  1959-07       Impact factor: 2.607

2.  MR diagnosis of brain death.

Authors:  K M Jones; P D Barnes
Journal:  AJNR Am J Neuroradiol       Date:  1992 Jan-Feb       Impact factor: 3.825

3.  Transcranial Doppler ultrasonography in raised intracranial pressure and in intracranial circulatory arrest.

Authors:  W Hassler; H Steinmetz; J Gawlowski
Journal:  J Neurosurg       Date:  1988-05       Impact factor: 5.115

4.  The role of transcranial Doppler in confirming brain death: sensitivity, specificity, and suggestions for performance and interpretation.

Authors:  G W Petty; J P Mohr; T A Pedley; T K Tatemichi; L Lennihan; D I Duterte; R L Sacco
Journal:  Neurology       Date:  1990-02       Impact factor: 9.910

5.  Practice parameters for determining brain death in adults (summary statement). The Quality Standards Subcommittee of the American Academy of Neurology.

Authors: 
Journal:  Neurology       Date:  1995-05       Impact factor: 9.910

6.  Results of four technical investigations in fifty clinically brain dead patients.

Authors:  R Nau; H W Prange; J Klingelhöfer; B Kukowski; D Sander; R Tchorsch; K Rittmeyer
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

7.  Electroencephalographic activity after brain death.

Authors:  M M Grigg; M A Kelly; G G Celesia; M W Ghobrial; E R Ross
Journal:  Arch Neurol       Date:  1987-09

8.  The combined monitoring of brain stem auditory evoked potentials and intracranial pressure in coma. A study of 57 patients.

Authors:  L García-Larrea; F Artru; O Bertrand; J Pernier; F Mauguière
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

9.  MR 'hot nose sign' and 'intravascular enhancement sign' in brain death.

Authors:  W W Orrison; A M Champlin; O L Kesterson; M F Hartshorne; J N King
Journal:  AJNR Am J Neuroradiol       Date:  1994-05       Impact factor: 3.825

10.  Determination of brain death with use of color duplex scanning in the intensive care unit setting.

Authors:  G W Lemmon; R W Franz; N Roy; M C McCarthy; J B Peoples
Journal:  Arch Surg       Date:  1995-05
View more
  1 in total

1.  Pupil diameter for confirmation of brain death in adult organ donors in Japan.

Authors:  Katsuyuki Sagishima; Yoshihiro Kinoshita
Journal:  Acute Med Surg       Date:  2016-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.